Search results
Jump to navigation
Jump to search
- substance or treatment of no therapeutic value6 statements, 0 sitelinks - 08:42, 26 November 2023
- for a medical treatment, an effect that is attributable to an expectation that the regimen will have an effect3 statements, 0 sitelinks - 08:42, 26 November 2023
- * [[Meds (album)|''Meds'' (album)]], by the rock band Placebo ...327 bytes (47 words) - 22:32, 8 January 2023
- ...besides metformin). Patients received either 50 mg ipragliflozin or a placebo. The drugs were identical in all physical forms. The patients were prohibit ...emoglobin A<sub>1c</sub>]] were −0.94% and −0.47% in the ipragliflozin and placebo groups, respectively (between-group difference −0.46%, [[p-value|''p'']] <0 ...7 KB (1,058 words) - 21:01, 20 February 2024
- ...besides metformin). Patients received either 50 mg ipragliflozin or a placebo. The drugs were identical in all physical forms. The patients were prohibit ...emoglobin A<sub>1c</sub>]] were −0.94% and −0.47% in the ipragliflozin and placebo groups, respectively (between-group difference −0.46%, [[p-value|''p'']] <0 ...7 KB (1,098 words) - 21:00, 20 February 2024
- ...nificant]] difference exists in the occurrence of [[hypoglycemia]] between placebo and sitagliptin. In those taking [[sulphonylurea]]s, the risk of [[hypoglyc ...liptin has been shown to lower [[HbA1c]] level by about 0.7% points versus placebo. It is slightly less effective than metformin when used as a [[monotherapy] ...8 KB (1,202 words) - 20:17, 12 March 2024
- ...nificant]] difference exists in the occurrence of [[hypoglycemia]] between placebo and sitagliptin. In those taking [[sulphonylurea]]s, the risk of [[hypoglyc ...liptin has been shown to lower [[HbA1c]] level by about 0.7% points versus placebo. It is slightly less effective than metformin when used as a [[monotherapy] ...9 KB (1,250 words) - 20:17, 12 March 2024
- ...民間療法で使用されていた植物[[phytochemical/ja|植物化学物質]]に基づいているものもある。研究者らは、代替療法の多くは「統計的に[[placebo/ja|偽薬]]治療と区別できない」と述べている。 ...ば、持っていない場合もある。多くは単に[[:en:tradition|伝統]]や[[:en:habituation|習慣]]の結果として、あるいは[[placebo effect/ja|プラセボ効果]]を誘発するのに有効であるために使用されている。 ...23 KB (786 words) - 22:26, 17 March 2024
- ...f it results in weight loss that is statistically significant greater than placebo and generally at least five percent of body weight over six months that com !placebo-adjusted percent bodyweight lost (highest dose studied) ...17 KB (2,406 words) - 18:16, 7 March 2024
- ...f it results in weight loss that is statistically significant greater than placebo and generally at least five percent of body weight over six months that com !placebo-adjusted percent bodyweight lost (highest dose studied) ...18 KB (2,460 words) - 18:15, 7 March 2024
- ...patients shows improvement in the control of glucose, when compared with [[placebo|placebos]], [[metformin]], [[sulfonylurea]], [[thiazolidinediones]], insuli ..., summed up, were that 10 mg of dapagliflozin showed more effect than placebo in the control of glucose, when given for 24 weeks. However, no inferior ef ...17 KB (2,477 words) - 09:56, 14 February 2024
- ...patients shows improvement in the control of glucose, when compared with [[placebo|placebos]], [[metformin]], [[sulfonylurea]], [[thiazolidinediones]], insuli ..., summed up, were that 10 mg of dapagliflozin showed more effect than placebo in the control of glucose, when given for 24 weeks. However, no inferior ef ...17 KB (2,553 words) - 09:56, 14 February 2024
- ...ration sulfonylureas relative to metformin (RR 1.0), insulin (RR 1.0), or placebo. The FDA requires sulfonylureas to carry a label warning regarding increase ...12 KB (1,572 words) - 20:36, 12 March 2024
- ...uck氏は、2型糖尿病患者の血糖コントロールにおけるSGLT-2阻害薬の活性に関する研究の[[Meta-analysis/ja|メタ解析]]では、[[placebo/ja|プラセボ]]、[[metformin/ja|メトホルミン]]、[[sulfonylurea/ja|スルホニルウレア]]、[[thiazolidi ...21 KB (632 words) - 15:58, 14 February 2024
- ...ration sulfonylureas relative to metformin (RR 1.0), insulin (RR 1.0), or placebo. The FDA requires sulfonylureas to carry a label warning regarding increase ...12 KB (1,638 words) - 20:35, 12 March 2024
- ...d with a 58% increased risk of developing acute pancreatitis compared with placebo or no treatment. ...6 KB (770 words) - 17:34, 12 March 2024
- シタグリプチンによる副作用は、まれに[[nausea/ja|吐き気]]、[[common cold/ja|感冒]]様症状、光線過敏症を除き、[[placebo/ja|プラセボ]]と同様である。シタグリプチンは下痢のリスクを増加させない。[[hypoglycemia/ja|低血糖]]の発現には、プラセボとシタグ ...10 KB (637 words) - 22:17, 12 March 2024
- ...d with a 58% increased risk of developing acute pancreatitis compared with placebo or no treatment. ...6 KB (812 words) - 17:34, 12 March 2024
- ...alternative treatments are "statistically indistinguishable from [[Placebo|placebo treatments]]". ...] or [[Habituation|habit]] or because they are effective in inducing the [[placebo effect]]. ...18 KB (2,575 words) - 16:03, 17 March 2024
- ...reduce heart attack, stroke, and cardiovascular death by 25% relative to a placebo in those with statin-resistant hypertriglyceridemia. ...en either 600 mg/day DHA alone, 600 or 1800 mg/day EPA alone, or placebo for six weeks. The DHA group showed a significant 20% drop in triglycerides ...12 KB (1,765 words) - 20:40, 14 April 2024